RPG Life Subsidiary Acquires API Business for ₹135 Crore

Date: September 02, 2026

The Board of Directors meeting was held on Wednesday, September 02, 2026
Meeting commenced at 7:00 pm and concluded at 8:10 pm
Board approved execution of Business Transfer Agreement by wholly owned subsidiary RPG Active Pharma Limited with Raghava Life Sciences Private Limited

RPG Active Pharma Limited (RPGAP), a wholly owned subsidiary, will acquire the Active Pharmaceutical Ingredients (APIs) and intermediates Businesses of Raghava Life Sciences Private Limited
Acquisition is structured as a slump sale of the business undertaking as a going concern
The transaction includes:
Manufacturing facilities
R&D facility
Portfolio of 29 API molecules (22 commercialized, 7 under development)
Business with revenues of approximately ₹19 Crores in FY26 (unaudited)
No shares are being purchased in any entity
No entity is being acquired

Consideration: Cash consideration up to ₹135 crores (Rupees One Hundred and Thirty-Five crores)
Consideration subject to customary adjustments and applicable taxes
Expected completion timeline: Tentatively within 30 days or such period as may be mutually agreed
Subject to satisfaction of closing conditions and regulatory approvals

Not a related party transaction
Promoter/Promoter Group/Group Companies have no interest in the entity whose assets are being acquired
Transaction requires regulatory approvals including approvals from local authorities

The acquisition aligns with the Company's strategy to expand its API business through its subsidiary company
The business being acquired pertains to the Pharmaceutical Industry

Disclosure made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Additional details provided as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026